Seeking Alpha

Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study...

Navidea Biopharmaceuticals' (NAVB +3%) announces "positive results" from a meta-analysis study of two Phase III trials that compared its Lymphoseek radiopharmaceutical injection with a commonly used agent. Lymphoseek "demonstrated reliable detection of lymph nodes" in patients with breast cancer and melanoma over a period of 15 minutes up to 30 hours, a time range that may be encountered in a clinic. (PR)
Comments (1)
  • joelkatz
    , contributor
    Comments (527) | Send Message
     
    NAVB has hit its bottom at $2.38, guys and gals, time to join and get in.
    12 Jun 2013, 11:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs